Practice
Short cuts
Pioglitazone may reduce cardiovascular risk in adults with type 2 diabetes
BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7580.1212 (Published 07 December 2006) Cite this as: BMJ 2006;333:1212Pioglitazone is an antidiabetic drug that works by reducing insulin resistance. It may also help reduce the risk of cardiovascular disease in adults with type 2 diabetes, according to a recent randomised trial.
The trial was based in Chicago and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.